Gilead Extends Tender Offer to Acquire Arcellx

Got story updates? Submit your updates here. ›

Gilead Sciences, a leading biopharmaceutical company, has extended its tender offer to acquire Arcellx, a clinical-stage cell therapy company, in a deal valued at $4.9 billion. The extension allows Gilead more time to complete the acquisition, which will expand its portfolio of innovative cell-based therapies.

Why it matters

The acquisition of Arcellx would bolster Gilead's position in the rapidly growing cell therapy market, which is seen as a promising area for treating various cancers and autoimmune diseases. The deal reflects Gilead's strategy to diversify its pipeline and strengthen its capabilities in cell-based medicines.

The details

Gilead initially announced its intent to acquire Arcellx in February 2026. The tender offer, which was set to expire on March 31, 2026, has now been extended to April 14, 2026, to allow for the completion of the transaction. Arcellx's lead product candidate, CART-ddBCMA, is currently in late-stage clinical trials for the treatment of multiple myeloma.

• Gilead initially announced its intent to acquire Arcellx in February 2026.
• The tender offer was set to expire on March 31, 2026, but has now been extended to April 14, 2026.

What they’re saying

What’s next

Gilead expects to complete the acquisition of Arcellx by the end of April 2026, subject to the satisfaction of customary closing conditions and regulatory approvals.